BioSpace News Archive

- Limited to Proposal 3, Amendment to Certificate of Incorporation to Increase Authorized Common Stock - Proposals 1, 2, and 4 were approved at the Annual Meeting - Scheduled to Reconvene July 8, 2021, 9:00 a.m. Eastern Daylight Time.

Expands Global Access to Exceptional Quality Diagnostic-like CT Images for Medical Care Teams Using the Radixact System.

FluroTech LTD. and wholly owned subsidiary FluroTest Diagnostic Systems, a diagnostics technology leader in high output rapid antigen testing for the detection of SARS-CoV-2 and other pathogens, are pleased to announce the appointment of former U.S. Public Health Service and Four-Star Admiral Joxel Garcia, M.D. to Chief Medical Officer.

Catalyst Biosciences, Inc. announced that members of its executive management team will participate in fireside chats at the two investor conferences in June: Raymond James Human Health Innovation Conference and the JMP Securities Life Sciences Conference.

10x Genomics, Inc. announced it is shipping its new Visium Spatial Gene Expression for FFPE assay.

Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced the appointment of Jane Huang, M.D. to its Board of Directors.

Veranome Biosystems LLC and Portal Bioscience LLC today announced the companies have entered into a co-development agreement to develop cutting-edge products that overcome the analytical challenges posed by the varying levels of RNA degradation often found in clinical specimens.

Ossianix, an antibody engineering company, and the University of Graz today announced the publication of a preclinical study that describes discovery of highly potent neutralizing single domain shark antibodies (VNARs) directed against the SARS-CoV-2 spike protein.

DaVita Kidney Care and the National Kidney Foundation announced their collaboration in launching an innovative, yearlong pilot aimed at improving health equity in kidney transplantation with a newly-developed program within NKF’s THE BIG ASK: THE BIG GIVE platform.

NiKang Therapeutics Inc. today announced the appointment of Robert (Xiaohua) Xin, M.D., Ph.D., as Chief Medical Officer.